From: Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study
Extent of stage | Ovarian cancer without VTE | Ovarian cancer less than 4 months after VTE | Ovarian cancer 4 months to 27 years after VTE | ||
---|---|---|---|---|---|
(n = 12,707) | (n = 50) | (n = 78) | |||
Prevalence Ratio (95% CI)a | Prevalence Ratio (95% CI)a | ||||
Patients with data on stage | 11,946 (94%) | 47 (94%) | 68 (87%) | ||
Stage I | 1,432 (12%) | 3 (6%) | 9 (13%) | ||
Stage II | 1,600 (13%) | 8 (17%) | 7 (10%) | ||
Stage III | 5,229 (44%) | 20 (43%) | 28 (41%) | ||
Stage IV | 3,685 (31%) | 16 (34%) | 1.1 (0.8–1.5) | 24 (35%) | 1.1 (0.8–1.5) |